Company profile
ACTINIUM PHARMACEUTICALS, INC.
AMEX:ATNMBiotechnology: Pharmaceutical Preparations
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02998047 | phase1 | terminated | 2016-12-01 | 2020-05-01 | Actinium Pharmaceuticals | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma |
| NCT02575963 | phase1_2 | completed | 2012-10-01 | 2018-11-01 | Actinium Pharmaceuticals | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients |
| NCT07157514 | phase2_3 | not_yet_recruiting | 2026-01-01 | 2029-02-01 | Actinium Pharmaceuticals | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML |
| NCT02665065 | phase3 | active_not_recruiting | 2016-06-01 | 2022-06-01 | Actinium Pharmaceuticals | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia |
| NCT03867682 | phase1_2 | unknown | 2020-01-15 | 2023-11-01 | Actinium Pharmaceuticals | Venetoclax and Lintuzumab-Ac225 in AML Patients |
FDA applications (0)
No records yet.